Effectiveness of apremilast against Behçet's disease-associated mucocutaneous and joint involvement confirmed through switching from adalimumab

Clin Exp Rheumatol. 2022 Sep;40(8):1605-1606. doi: 10.55563/clinexprheumatol/icqg9x. Epub 2022 Sep 15.

Authors

Naoto Azuma¹, Kiyoshi Matsui²

Affiliations

¹ Division of Diabetes, Endocrinology and Clinical Immunology, Department of Internal Medicine, Hyogo Medical University, Nishinomiya, Japan. naoazuuh@hyo-med.ac.jp.
² Division of Diabetes, Endocrinology and Clinical Immunology, Department of Internal Medicine, Hyogo Medical University, Nishinomiya, Japan.

PMID: 36106543
DOI: 10.55563/clinexprheumatol/icqg9x

No abstract available

Publication types

Letter

MeSH terms

Adalimumab* / therapeutic use
Anti-Inflammatory Agents, Non-Steroidal* / therapeutic use
Behcet Syndrome* / diagnosis
Behcet Syndrome* / drug therapy
Humans
Thalidomide / analogs & derivatives
Thalidomide / therapeutic use

Substances

Anti-Inflammatory Agents, Non-Steroidal
Thalidomide
Adalimumab
apremilast